Introduction
When transthoracic echocardiogram does not provide adequate visualization, a transoesophageal echocardiogram (TEE) may be necessary in patients undergoing several interventional procedures such as transcoronary ablation of septal hypertrophy (TASH), patent foramen ovale (PFO) closure, percutaneous aortic valve implantation (PAVI), and aortic valvuloplasty for aortic valve stenosis. The percutaneous approach to aortic valve stenosis minimizes the surgical trauma 1 and haemodynamic changes associated with general anaesthesia and positive pressure ventilation, and is increasingly used in critically ill patients with severe aortic stenosis and severe comorbidities even under local anaesthesia. 2 -4 Transoesophageal echocardiography examination is associated with temporary arterial oxygen tension worsening during and after uncomplicated echo examination, and patients with severe cardiac disease are at risk of developing respiratory failure or serious cardiac arrhythmias under these circumstances. On the other hand, general anaesthesia is associated with significant potential complications and sedation carries a high risk of acute respiratory failure in orthopnoeic patients.
Non-invasive ventilation (NIV) may avoid many of the complications of invasive mechanical ventilation while ensuring a similar degree of efficacy in a wide range of conditions 5, 6 ; so far, NIV has never been reported as an aid to TEE examination. We report the use of NIV delivered by a modified mask in orthopnoeic patients undergoing continuous TEE under sedation during percutaneous treatment of aortic valve stenosis.
Methods

Patients
We report data from three orthopnoeic patients, two males and one female, respectively, aged 83, 84, and 88, all in NYHA class 3, with severe aortic valve stenosis scheduled for percutaneous treatment on the basis of a logistic EuroSCORE .20% and coexisting comorbidities. All patients were extensively informed about the anaesthesiological options and gave written informed consent to the procedure, and to the scientific use of anonymous clinical data.
Percutaneous aortic valve implantation
All patients underwent transfemoral percutaneous procedures in the cardiac catheterization laboratory with operating theatre-like sterile precautions as described elsewhere. 3, 4 Intraoperative monitoring consisted of five-lead electrocardiogram, pulsoximetry, invasive arterial pressure by radial artery cannulation, central venous pressure through internal jugular vein cannulation, TEE, temperature, urine output, and serial arterial blood gas analysis. In the two patients scheduled for PAVI balloon valvuloplasty with a 20 -23 mm balloon under rapid right ventricular pacing was performed before CoreValve w (Medtronic, CV Luxembourg S.a.r.l.) deployment. Then the device was directed over a stiff guidewire, placed in the left ventricle, and deployed retrogradely under fluoroscopic and TEE guidance. In the patient undergoing isolated valvuloplasty, the procedure was performed with a 23 mm balloon under rapid right ventricular pacing. Transoesophageal echocardiography was performed using an omniplane probe (4 -7 Hz) and IE33 echocardiography system (Philips, Amsterdam, The Netherlands) in all patients.
Anaesthesia
All patients were premedicated with intramuscular atropine 0.01 mg/kg 60 min previous the procedure to avoid salivation during NIV. Preoperative fasting, at least 2 h for fluids and 6 h for solids, was requested in order to prevent pulmonary aspiration, 7 and the TEE probe was maintained in oesophageal position during the procedure to avoid opening of the oesophageal sphincter and regurgitation of gastric content. Local anaesthesia consisted of 1% lidocaine injected subcutaneously at the arterial and venous femoral access sites. The oropharyngeal local anaesthesia was obtained with spray lidocaine 2% in sitting position before starting NIV. Sedation, initiated after TEE probe insertion, was accomplished with remifentanil infusion (starting dose 0.02 mg/kg/min) adjusted according to the response sedation scale (target level: score 2 -3 with modified Wilson scale) 8 and procedural requirements. Remifentanil, a potent short-acting opioid whose use is approved for only by anaesthesia care providers, was always given by a cardiac anaesthetist.
Non-invasive ventilation
Non-invasive ventilation was delivered by a ventilator specifically designed for NIV (Vision, Respironics, Inc.
w , Murrysville, PA, USA) connected through a monotube circuit to an adult oro-nasal mask (VIP 75 TM 7500 Series Oro-Nasal V masks TM for Non-Invasive Ventilation, Hans Rudolph, Inc., Kansas City, MO, USA). In all cases, the TEE probe was passed through a vertical hole (Figure 1 ) obtained on the anterior part of the mask by a surgical cutter. Visual monitoring of ventilator display confirmed leak-free ventilation during TEE probe manipulation, thus avoiding inadequate ventilatory support. In all patients, NIV was used in pressure support modality. The ventilator was set at an inspiratory positive airway pressure between 8 and 12 cmH 2 O, a positive end expiratory pressure of 4 -6 cmH 2 O, an inspiratory oxygen fraction (FiO 2 ) between 0.35 and 0.50 in order to maintain a pulsoximetry arterial oxygen saturation (SaO 2 ) .92%, arterial CO 2 tension (PaCO 2 ) ,50 mmHg throughout the procedure. A back-up respiratory rate of 10 bpm was set. Non-invasive ventilation was started in the sitting position and maintained for 15 min in all cases to allow the patient to adapt to both the mask and the ventilator setting. Thereafter, the patient was placed in the supine position under NIV and the TEE probe gently introduced through the hole in the mask. Non-invasive ventilation was administered throughout the procedure in all cases. According to our protocol, after the aortic valve procedure all patients were transferred to the intensive care unit (ICU) where NIV was continued for 2 h. 
Discussion
Due to orthopnoea, patients with severe aortic valve stenosis may be unsuitable either for TEE monitored PAVI, neither for TEE monitored valvuloplasty, unless general anaesthesia is performed. However, general anaesthesia is associated with significant potential complications, particularly respiratory complications, and it is poorly tolerated by high-risk cardiac patients. Such patients gain important advantages from minimally invasive anaesthetic techniques. 9 The technique we describe allowed gentle conduction of the procedure, with the patient lightly sedated but always cooperative. The mask and the TEE were well tolerated in all cases while orthopnoeic patients were lying in the supine position throughout the procedure. Non-invasive ventilation proved effective in preventing respiratory failure due to sedation. The described technique could be used in other settings where critically ill patients with poor cardiac and respiratory function need a TEE examination, such as patients admitted to the intensive care or coronary units for myocardial infarction, 10 or those undergoing TASH or PFO closure. However it must be emphasized that NIV for TEE procedures under sedation has some limitations: (1) airways are not protected: careful monitoring of the sedation level is therefore mandatory; (2) the patient's cooperation is essential; (3) the entire procedure must be performed under close monitoring of vital signs and oxygen saturation. Moreover, remifentanil is a potent opioid with potential side effects, like muscle rigidity, which may make NIV difficult or impossible, so it should be always administered by anaesthetists experienced in remifentanil sedation during NIV.
In conclusion, in a case series of three high-risk orthopnoeic patients with cardiac disease, NIV delivered by a modified facemask with a hand-made vertical hole allowed safe continuous TEE examination in lightly sedated patients. Non-invasive ventilation is promising in that it offers an aid to alleviate dyspnoea and to prevent respiratory failure during TEE under sedation.
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